{"id":48988,"date":"2022-09-29T18:01:48","date_gmt":"2022-09-29T16:01:48","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/"},"modified":"2022-09-29T18:01:48","modified_gmt":"2022-09-29T16:01:48","slug":"church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/","title":{"rendered":"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28"},"content":{"rendered":"
\n

EWING, N.J.–(BUSINESS WIRE)–Church & Dwight Co., Inc. (NYSE: CHD) will host a conference call to discuss third quarter 2022 earnings results on October 28, 2022, at 10:00 a.m. ET.\n<\/p>\n

<\/a><\/p>\n

\nMedia and investors may access the live audio webcast at www.churchdwight.com<\/a> beginning at 10:00 a.m. ET. The webcast will also be available for replay.\n<\/p>\n

\nChurch & Dwight Co., Inc., founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda. The Company manufactures and markets a wide range of personal care, household and specialty products under recognized brand names such as ARM & HAMMER\u00ae, TROJAN\u00ae, OXICLEAN\u00ae, SPINBRUSH\u00ae, FIRST RESPONSE\u00ae, NAIR\u00ae, ORAJEL\u00ae, XTRA\u00ae, L\u2019IL CRITTERS\u00ae and VITAFUSION\u00ae, BATISTE\u00ae, WATERPIK\u00ae, ZICAM\u00ae, FLAWLESS\u00ae, THERABREATH\u00ae, and following the closing of the transaction, HERO MIGHTY PATCH\u00ae. These 15 key brands represent approximately 85% of the Company\u2019s product sales. For more information, visit the Company\u2019s website.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRick Dierker
\n
609-806-1900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

EWING, N.J.–(BUSINESS WIRE)–Church & Dwight Co., Inc. (NYSE: CHD) will host a conference call to discuss third quarter 2022 earnings results on October 28, 2022, at 10:00 a.m. ET. Media and investors may access the live audio webcast at www.churchdwight.com beginning at 10:00 a.m. ET. The webcast will also be available for replay. Church & … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48988","6":"format-standard","7":"category-industry"},"yoast_head":"\nChurch & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EWING, N.J.–(BUSINESS WIRE)–Church & Dwight Co., Inc. (NYSE: CHD) will host a conference call to discuss third quarter 2022 earnings results on October 28, 2022, at 10:00 a.m. ET. Media and investors may access the live audio webcast at www.churchdwight.com beginning at 10:00 a.m. ET. The webcast will also be available for replay. Church & ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T16:01:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220929005764\/en\/523463\/21\/AH_logo_-_tm.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28\",\"datePublished\":\"2022-09-29T16:01:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/\"},\"wordCount\":165,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005764\\\/en\\\/523463\\\/21\\\/AH_logo_-_tm.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/\",\"name\":\"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005764\\\/en\\\/523463\\\/21\\\/AH_logo_-_tm.jpg\",\"datePublished\":\"2022-09-29T16:01:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005764\\\/en\\\/523463\\\/21\\\/AH_logo_-_tm.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005764\\\/en\\\/523463\\\/21\\\/AH_logo_-_tm.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/","og_locale":"en_US","og_type":"article","og_title":"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28 - Pharma Trend","og_description":"EWING, N.J.–(BUSINESS WIRE)–Church & Dwight Co., Inc. (NYSE: CHD) will host a conference call to discuss third quarter 2022 earnings results on October 28, 2022, at 10:00 a.m. ET. Media and investors may access the live audio webcast at www.churchdwight.com beginning at 10:00 a.m. ET. The webcast will also be available for replay. Church & ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-29T16:01:48+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220929005764\/en\/523463\/21\/AH_logo_-_tm.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28","datePublished":"2022-09-29T16:01:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/"},"wordCount":165,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220929005764\/en\/523463\/21\/AH_logo_-_tm.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/","url":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/","name":"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220929005764\/en\/523463\/21\/AH_logo_-_tm.jpg","datePublished":"2022-09-29T16:01:48+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220929005764\/en\/523463\/21\/AH_logo_-_tm.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220929005764\/en\/523463\/21\/AH_logo_-_tm.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/church-dwight-to-webcast-discussion-of-third-quarter-2022-results-on-october-28\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Church & Dwight to Webcast Discussion of Third Quarter 2022 Results on October 28"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48988"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48988\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}